期刊
CURRENT PHARMACEUTICAL DESIGN
卷 13, 期 15, 页码 1607-1616出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138161207780765918
关键词
-
资金
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062244, R01HL052622] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038060] Funding Source: NIH RePORTER
- NHLBI NIH HHS [R01 HL062244-07, R01 HL062244, R01 HL052622-09, R01 HL052622] Funding Source: Medline
- NIGMS NIH HHS [R01 GM038060-19, R01 GM038060] Funding Source: Medline
Heparin is a glycosaminoglycan mixture currently used in prophylaxis and treatment of thrombosis. Heparin possesses non-anticoagulant properties, including modulation of various proteases, interactions with fibroblast growth factors, and anti-inflammatory actions. Senile dementia of Alzheimer's type is accompanied by inflammatory responses contributing to irreversible changes in neuronal viability and brain function. Vascular factors are also involved in the pathogenesis of senile dementia. Inflammation, endogenous proteoglycans, and assembly of senile plagues and neurofibrillary tangles contribute directly and indirectly to further neuronal damage. Neuron salvage can be achieved by antiinflammation and the competitive inhibition of proteoglycans accumulation. The complexity of the pathology of senile dementia provides numerous potential targets for therapeutic interventions designed to modulate inflammation and proteoglycan assembly. Heparin and related oligosaccharides are known to exhibit anti-inflammatory effects as well as inhibitory effects on proteoglycan assembly and may prove useful as neuroprotective agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据